Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00034892
Status:
COMPLETED
Last Update Posted:
2013-01-04
First Post:
2002-05-02
Brief Title:
CAFE Comparison of Atypicals in First Episode of Psychosis
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Efficacy and Tolerability of Olanzapine Quetiapine and Risperidone in the Treatment of First Episode Psychosis A Randomized Double Blind 52-Week Comparison
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the effectiveness tolerability and efficacy of the currently available atypical antipsychotic drugs olanzapine 25-20 mgday quetiapine 100-800 mgday and risperidone 05-4 mgday in patients with schizophrenia schizophreniform disorder or schizoaffective disorder who are experiencing their first psychotic episode
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None